Scancell Holdings plc (SCLP.L) LSE
Currency In GBp
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In GBp
Address
Unit 202 Bellhouse Building
Oxford, OX4 4GD
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 18 6558 2066
Website
Sector
Healthcare
Industry
Biotechnology
Employees
61
First IPO Date
February 12, 2010
| Name | Title | Pay | Year Born |
| Phillip John L'Huillier | Chief Executive Officer & Director | 391,966 | 1962 |
| Lindy Gillian Durrant | Chief Scientific Officer, Director & Founder | 386,797 | 1957 |
| Callum Scotthasbeen | Senior Vice President of Development | 0 | N/A |
| Mandeep Sehmi | Head of Business Development | 0 | N/A |
| Nermeen Varawalla DPHIL | Chief Medical Officer | 0 | 1962 |
| Samantha Paston | Head of Translational Research | 0 | N/A |
| Shamim Kazmi Stokes | Head of Programme Management | 0 | N/A |
| Alex Hayward | Finance Director & Company Secretary | 0 | N/A |
| David Schilansky | Interim Chief Financial Officer | 0 | 1975 |
| Philip Angell-Manning | Head of CMC | 0 | N/A |
Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The company's pipeline features several promising candidates, including SCIB1, currently in Phase II clinical trials for metastatic melanoma; SCIB2, aimed at non-small cell lung cancer; and Modi-1, which is undergoing Phase I/II studies for various indications such as head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is advancing Modi-2, a therapeutic agent specifically designed to target homocitrullinated cancer antigens. Its development efforts also encompass SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine engineered to provide protection against the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.